Sun Pharma Advanced Research Co Ltd

Sun Pharma Advanced Research Co Ltd

SPARC

 134.41
 1.40
1.05%
Healthcare
 0.00
(%)1D
Updated: 02 Jan 2026, 03:31:09 pm IST
Stock Score

Trouble loading chart

Open Price
 133.39
Prev. Close
 133.01
 133.18
Day Low
 134.88
Day High

 108.48
52 Week Low
 201.73
52 Week High

Quick Bite

Price To Earnings Ratio

-16.33

Sector PE

37.35

PB Ratio

-20.12

Sector PB

5.27

EPS

-8.23

Dividend Yield

0.00

Today's Volume

416.494 K

5 Day Avg. Volume

443.770 K

PEG Ratio

-1.41

Market Cap.

₹ 4,350.00 Cr.

About Sun Pharma Advanced Research Co Ltd

Sun Pharma Advanced Research Company Limited is an India-based clinical-stage biopharmaceutical company that focuses on developing therapeutics to improve standards of care for patients worldwide. The Company's therapeutic focus is in the area of oncology, neurology and immunology. Its lead oncology programs include vodobatinib (SCO-088), a BCR-ABL targeting tyrosine kinase inhibitor for refractory chronic myelogenous leukemia, and an anti-MUC-1 antibody-drug conjugate (ADC) with the potential to treat multiple cancers. The Company's other programs include Sezaby for the treatment of neonatal seizures, Vodobatinib for the treatment of neurodegenerative disorders (SCC-138), Vibozilimod for the treatment of autoimmune disorders (SCD-044), SCD-153 for the treatment of alopecia areata, SBO-154 for multiple cancer indications and SCO-155 for treatment of cancer. SBO-154 is an anti MUC1 ADC being developed for multiple tumor types expressing MUC1.

Sun Pharma Advanced Research Co Ltd Share Price

Sun Pharma Advanced Research Company Limited is an Indian clinical stage biopharmaceutical company. The company is engaged in R&D (RandD) of pharmaceutical products for unmet medical needs in the fields of oncology, neurodegeneration and immunology. The company develops new chemical entities (NCEs), new biological entities and reformulated products. Its NICE includes SCC-138, SCO-088, SCO-120 and SCD-044. Its new drug delivery systems (NDDS) include Wrap Matrix technology, Lipexelle technology and TearAct technology. Wrap Matrix technology is useful in the development of controlled release tablets. It developed Elepsia XR using Wrap MatrixTM technology. Lipexelle technology for ophthalmic formulations. The company also developed Xelpros, a BAK-free latanoprost eye drop developed with Lipexelle technology. Xelpros is marketed by its partner in the United States. He also developed PDP-716 eye drops based on TearAct technology for the treatment of glaucoma.

Sun Pharma Advanced Research Co Ltd FAQs

How to Buy Sun Pharma Advanced Research Co Ltd Share?

up
To purchase Sun Pharma Advanced Research Co Ltd shares, you can open a Demat & Trading account through a broker or financial institution. Once your account is set up and funded, search for Sun Pharma Advanced Research Co Ltd (ticker symbol: SPARC) on the trading platform provided by your broker and purchase the shares.

What's Sun Pharma Advanced Research Co Ltd share price today?

up
The stock price of Sun Pharma Advanced Research Co Ltd as of 05 Jan 2026 is ₹134.41

What is the Market Cap of Sun Pharma Advanced Research Co Ltd?

up
Market capitalisation represents the total market value of a company's outstanding shares. As of 05 Jan 2026, Sun Pharma Advanced Research Co Ltd (ticker symbol: SPARC) has a market capitalisation of approximately ₹43,50,00,00,000.00

What is the PE and PB ratio of Sun Pharma Advanced Research Co Ltd?

up
Sun Pharma Advanced Research Co Ltd Ltd's price-to-book ratio as of 05 Jan 2026 is -20.12, reflecting the market's valuation compared to its asset value. As of 05 Jan 2026, the trailing twelve months P/E (price-to-earnings) ratio is -16.33, indicating the market values the company at around - ₹16.33 for every ₹1 of earnings

What is the 52 Week High and Low of Sun Pharma Advanced Research Co Ltd Share?

up
Sun Pharma Advanced Research Co Ltd Ltd (SPARC) hit its 52-week high at ₹201.73, and its 52-week low at ₹108.48.
Begin your investment journey today
Login/Register
Start Now